Vero Biotech, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vero Biotech, Inc. - overview
Established
2006
Location
Atlanta, GA, US
Primary Industry
Biotechnology
About
Based in Georgia, US, and founded in 2006, Vero Biotech, Inc. , a. k. a.
Vero Biotech operates as a biotechnology company that focuses on design, development, and commercialization of inhaled nitric oxide (NO) delivery systems for patients with cardiopulmonary conditions. In February 2024, Vero Biotech, Inc. raised USD 65 million in venture debt funding from Horizon Technology Finance. As of July 2024, Brent Furse is the CEO of the company.
Vero Biotech provides inhaled nitric oxide delivery systems, focusing on the treatment of persistent pulmonary hypertension in newborns (PPHN). The company’s GENOSYL® Delivery System facilitates the administration of inhaled nitric oxide, which helps dilate pulmonary vasculature and improve oxygenation, reducing the need for extracorporeal membrane oxygenation (ECMO). The company plans to use its proceeds from February 2024 funding to maintain the commercial growth of its research and development and Genosyl projects.
Current Investors
Runway Growth Capital, MVM Partners, Petrichor
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Cardiology, Diagnostic Equipment
Website
www.vero-biotech.com
Verticals
Manufacturing
Company Stage
Series E
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.